Lin R, Tarr P E, Jones T C
Clinical Research and Development, SANDOZ Pharma Ltd., Basel, Switzerland.
Clin Infect Dis. 1995 Dec;21(6):1439-49. doi: 10.1093/clinids/21.6.1439.
Vaccine adjuvants are expected to play an important role in enhancing the immunogenicity of existing and new-generation vaccines against infectious diseases. In particular, adjuvants should direct the immune response in the most appropriate manner--furthering, for example, an expanded B-cell response, a cytotoxic T-cell response, or a T-helper 1 or 2 subset response. While some noncytokine adjuvants have exerted potent effects, their modes of action are most likely mediated by cytokines. Several cytokines have already been shown to be efficient adjuvants in animal models and/or in clinical trials. The mechanisms of cytokine function must be better understood and the techniques for the use of cytokines improved if the full potential of these substances as vaccine adjuvants is to be realized. When used to best advantage, such adjuvants enhance the immunity induced by viral, bacterial, and parasitic vaccines and thereby promote efficient protection or even cure.
疫苗佐剂有望在增强现有和新一代传染病疫苗的免疫原性方面发挥重要作用。特别是,佐剂应以最适当的方式引导免疫反应——例如,促进B细胞反应、细胞毒性T细胞反应或辅助性T细胞1或2亚群反应的扩大。虽然一些非细胞因子佐剂已发挥了强大作用,但其作用方式很可能是由细胞因子介导的。几种细胞因子已在动物模型和/或临床试验中被证明是有效的佐剂。如果要充分发挥这些物质作为疫苗佐剂的潜力,就必须更好地理解细胞因子的功能机制,并改进使用细胞因子的技术。如果使用得当,此类佐剂可增强病毒、细菌和寄生虫疫苗诱导的免疫力,从而促进有效的保护甚至治愈。